Literature DB >> 12467887

Exocytosis mechanism as a new targeting site for mechanisms of action of antiepileptic drugs.

Motohiro Okada1, Gan Zhu, Shukuko Yoshida, Kazuaki Kanai, Shinichi Hirose, Sunao Kaneko.   

Abstract

Carbamazepine (CBZ) and zonisamide (ZNS) are effective antiepileptic drugs (AEDs) for the treatment of epilepsy and mood disorder. One of the mechanisms of action of CBZ and ZNS is inactivation of voltage-gated Na+ channel (VGSC). However, the major mechanism(s) of action of these AEDs is not clear yet. We have been exploring novel targeting mechanisms for the antiepileptic actions of CBZ and ZNS during the past ten years. In this report, we describe our hypothesis regarding the new targeting mechanisms for the antiepileptic action of AEDs. We determined an interaction between these AEDs and inhibitors of both voltage-sensitive Ca2+ channels (VSCCs) and soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) on neurotransmitter exocytosis using microdialysis. Perfusion with therapeutic concentrations of CBZ and ZNS increased basal neurotransmitter release. This stimulatory action was predominantly inhibited by inhibitors of N-type VSCC and syntaxin. CBZ and ZNS increased Ca2+-evoked release, an action selectively inhibited by inhibitors of N-type VSCC and syntaxin. CBZ and ZNS reduced K+-evoked release, an action predominantly inhibited by inhibitors of P-type VSCCs and synaptobrevin. These actions of CBZ and ZNS on neurotransmitter exocytosis could be observed under the condition of inhibition of VGSC using perfusion with tetrodotoxin. Our findings enhance our understanding of the mechanisms of action of CBZ and ZNS as AEDs, which possibly reduce P-type VSCCs/synaptobrevin-related exocytosis mechanisms during the depolarization stage, and simultaneously enhance N-type VSCCs/syntaxin-related exocytosis mechanisms at the resting stage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467887     DOI: 10.1016/s0024-3205(02)02283-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Truncations of amphiphysin I by calpain inhibit vesicle endocytosis during neural hyperexcitation.

Authors:  Yumei Wu; Shuang Liang; Yoshiya Oda; Iori Ohmori; Tei-ichi Nishiki; Kohji Takei; Hideki Matsui; Kazuhito Tomizawa
Journal:  EMBO J       Date:  2007-05-31       Impact factor: 11.598

Review 2.  The ongoing pursuit of neuroprotective therapies in Parkinson disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Nat Rev Neurol       Date:  2014-12-02       Impact factor: 42.937

3.  Zonisamide attenuates MPP+-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells.

Authors:  Vedat Ali Yürekli; Semih Gürler; Mustafa Nazıroğlu; Abdülhadi Cihangir Uğuz; Hasan Rifat Koyuncuoğlu
Journal:  Cell Mol Neurobiol       Date:  2012-11-15       Impact factor: 5.046

Review 4.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 5.  Astroglial Connexin43 as a Potential Target for a Mood Stabiliser.

Authors:  Motohiro Okada; Tomoka Oka; Misaki Nakamoto; Kouji Fukuyama; Takashi Shiroyama
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

6.  Anionic Species Regulate Chemical Storage in Nanometer Vesicles and Amperometrically Detected Exocytotic Dynamics.

Authors:  Xiulan He; Andrew G Ewing
Journal:  J Am Chem Soc       Date:  2022-03-07       Impact factor: 15.419

7.  Pathogenesis and pathophysiology of autosomal dominant sleep-related hypermotor epilepsy with S284L-mutant α4 subunit of nicotinic ACh receptor.

Authors:  Kouji Fukuyama; Masashi Fukuzawa; Takashi Shiroyama; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

Review 8.  Can rodent models elucidate the pathomechanisms of genetic epilepsy?

Authors:  Motohiro Okada
Journal:  Br J Pharmacol       Date:  2021-05-12       Impact factor: 9.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.